| Patent application number | Description | Published |
|---|
| 20090104153 | METHOD OF ELICITING IMMUNE RESPONSE - The present invention relates to methods of eliciting an immune response by use of a prime-boost schedule for delivering a polynucleotide encoding a heterologous non-self antigen. In particular, the invention relates to a prime-boost schedule wherein the priming polynucleotide composition is delivered by an adenoviral vector, and the boosting polynucleotide composition is coated on or incorporated in a particle and is administered by a particle acceleration device. | 04-23-2009 |
| 20090274726 | SYNTHETIC GENE - The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist. | 11-05-2009 |
| 20100047243 | NOVEL ANTIBODIES AGAINST IGF-IR - The present invention relates to antibodies or antigen binding fragments thereof which specifically binds to IGF-1R, specifically hIGF-1R. Also disclosed are antibody preparations comprising antibodies or antigen binding fragments of the invention. Methods of producing such antibodies or antigen binding fragments and uses thereof are also included within the scope of the present invention. | 02-25-2010 |
| 20100221260 | IMMUNOGLOBULINS - The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder. | 09-02-2010 |
| 20110008345 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 01-13-2011 |
| 20110105724 | NOVEL COMPOUNDS - The present invention relates to neutralizing antibodies (immunoglobulins) which are specific for human IL-8 and bind to as well as neutralize human IL-8. | 05-05-2011 |
| Patent application number | Description | Published |
|---|
| 20090104231 | VACCINE - The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines comprising polynucleotide sequences encoding HCV proteins, and methods of treatment of individuals infected with HCV comprising administration of the vaccines of the present invention. | 04-23-2009 |
| 20090123479 | IMMUNOGLOBULINS - The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA). | 05-14-2009 |
| 20090148905 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 06-11-2009 |
| 20090232847 | Immunogenic compositions - The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines that encode the HCV Core protein and a polynucleotide sequence that encodes at least one other HCV protein, wherein the vaccine causes expression of the proteins within the same cell and the sequence of the polynucleotide sequence encoding the core protein has been mutated or positioned relative to the polynucleotide sequence encoding the at least one other HCV protein such that the negative effect of expression of the Core protein upon the expression of the said at least one other HCV protein is reduced. | 09-17-2009 |
| 20100303821 | IMMUNOGLOBULINS - The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF. | 12-02-2010 |
